Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27248330 | 0.88 | L3MBTL1 (0.58) | HRH4HTR2CHTR2AL3MBTL1LMNA | |
| SCHEMBL27429695 | 0.87 | HRH4 (0.49) | HRH4HTR2CHTR2ACTSCL3MBTL1 | |
| SCHEMBL27430032 | 0.86 | HTR2C (0.60) | HRH4HTR2CHTR2AHTR3A | |
| SCHEMBL27429710 | 0.85 | HTR2C (0.64) | HRH4HTR2CHTR2ABRD4CCND3 | |
| SCHEMBL27248392 | 0.85 | HPGD (0.50) | HRH4HTR2CHTR2ACTSCKMT2A | |
| SCHEMBL27430722 | 0.84 | HTR2C (0.44) | HRH4HTR2CHTR2ACTSCL3MBTL1 | |
| SCHEMBL27248311 | 0.83 | HPGD (0.58) | HRH4HTR2CHTR2AL3MBTL1KMT2A | |
| SCHEMBL27429484 | 0.81 | BCL6 (0.66) | HRH4LMNABRD4BCL6 | |
| SCHEMBL27430034 | 0.81 | HTR2C (0.48) | HRH4HTR2CHTR2AL3MBTL1LMNA | |
| SCHEMBL27429988 | 0.80 | HTR2C (0.61) | HRH4HTR2CHTR2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199624-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION INC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024118607-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024118607-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199624-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | MSH2, KRAS, CHAMP1 | HRH4 4871/4885HTR2C 3424/4885HTR2A 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.